Ameriprise’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Ameriprise’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-15,135	Closed	-$560K	–	3821
2016 Q2	$560K	Buy	+15,135	New	+$593K	﹤0.01%	3116
2016 Q1	–	Sell	-5,991	Closed	-$303K	–	3834
2015 Q4	$303K	Sell	5,991 -3,969	-40%	-$196K	﹤0.01%	3483
2015 Q3	$455K	Sell	9,960 -3,179	-24%	-$178K	﹤0.01%	3307
2015 Q2	$767K	Sell	13,139 -1,274	-9%	-$72.8K	﹤0.01%	3248
2015 Q1	$795K	Buy	14,413 +9,626	+201%	+$520K	﹤0.01%	3028
2014 Q4	$240K	Buy	4,787 +1,372	+40%	+$67.1K	﹤0.01%	3425
2014 Q3	$158K	Buy	3,415 +1,130	+49%	+$50.9K	﹤0.01%	3492
2014 Q2	$100K	Sell	2,285 -286	-11%	-$11.6K	﹤0.01%	3587
2014 Q1	$106K	Sell	2,571 -1,528	-37%	-$65.4K	﹤0.01%	3485
2013 Q4	$152K	Buy	4,099 +3,399	+486%	+$122K	﹤0.01%	3251
2013 Q3	$25K	Buy	+700	New	+$23.2K	﹤0.01%	4263

Other funds holding PBE

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SAM

SignalPoint Asset Management Springfield, Missouri $411M AUM 23.81% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

Traynor Capital Management Malvern, Pennsylvania $1.7B AUM 39.15% 1-Year Est. Return

CAS

Cue Advisory Services Phoenix, Arizona $167M AUM 18.62% 1-Year Est. Return

Ameriprise's PBE Position: Q3 2016 in Review

Ameriprise sold out of Invesco Biotechnology & Genome ETF (PBE) in Q3 2016, closing a stake of 15,135 shares — an estimated $560K sold.

Ameriprise first reported a position in PBE in Q3 2013 and held it in 11 quarters. The position peaked at $795K in Q1 2015. 68 funds tracked by Wall St. Rank hold PBE as of Q3 2016.

Ameriprise reported no remaining Invesco Biotechnology & Genome ETF position as of Q3 2016 after selling out during the quarter.
Ameriprise sold 15,135 Invesco Biotechnology & Genome ETF shares in Q3 2016, an estimated $560K.
Ameriprise first reported a position in Invesco Biotechnology & Genome ETF in Q3 2013 and held it in 11 quarters.
Ameriprise's Invesco Biotechnology & Genome ETF position peaked at $795K in Q1 2015.
68 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2016.

Based on Ameriprise's 13F filing for Q3 2016, filed 8 Nov 2016.